



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ▶ NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here**  
Signature ▶ Stephen Bardin Date ▶ 1/28/2021  
007DCCFA87FF4A3...  
Print your name ▶ Stephen Bardin Title ▶ VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of Bekker</i>	12/14/2020		P00439876
	Firm's name ▶ BDO USA, LLP	Firm's EIN ▶ 13-5381590		Phone no. 616-774-7000	
Firm's address ▶ 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 355 shares of its common stock (“New Shares”) per 1,000 shares of stock of Adrenas Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Adrenas Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here**  
Signature ► Stephen Bardin Date ► 1/28/2021  
007DCCFA87FF4A3...  
Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of Bekker</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 31 shares of its common stock (“New Shares”) per 1,000 shares of stock of ASPA Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from ASPA Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

007DCCFA87FF4A3...

Signature ► Stephen Bardin Date ► 1/28/2021

Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP			Firm's EIN ►	13-5381590
	Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503			Phone no.	616-774-7000

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 328 shares of its common stock (“New Shares”) per 1,000 shares of stock of Calcilytix Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Calcilytix Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ► Stephen Bardin Date ► 1/28/2021  
 007DCCFA07FF4A3...  
 Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 40 shares of its common stock (“New Shares”) per 1,000 shares of stock of CoA Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from CoA Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ► Stephen Bardin Date ► 1/28/2021

Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 166 shares of its common stock (“New Shares”) per 1,000 shares of stock of Ferro Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Ferro Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ▶ NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ▶ Stephen Bardin Date ▶ 1/28/2021  
007DCCFA87FF4A3...

Print your name ▶ Stephen Bardin Title ▶ VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ▶ BDO USA, LLP	Firm's EIN ▶ 13-5381590		Phone no. 616-774-7000	
Firm's address ▶ 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 255 shares of its common stock (“New Shares”) per 1,000 shares of stock of Fortify Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Fortify Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ▶ NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ▶ Stephen Bardin Date ▶ 1/28/2021  
 007DCCFA07FF4A3...  
 Print your name ▶ Stephen Bardin Title ▶ VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of Bekker</i>	12/14/2020		P00439876
	Firm's name ▶ BDO USA, LLP	Firm's EIN ▶ 13-5381590		Phone no. 616-774-7000	
Firm's address ▶ 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

Fortify Therapeutics, Inc.

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 84 shares of its common stock (“New Shares”) per 1,000 shares of stock of Molecular Skin Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Molecular Skin Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► YES

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT


\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
  
 Signature ► 007DCCCEA87FF4A3 Date ► 1/28/2021

Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER		12/14/2020		P00439876
	Firm's name ► BDO USA, LLP			Firm's EIN ►	13-5381590
	Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503			Phone no.	616-774-7000

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 226 shares of its common stock (“New Shares”) per 1,000 shares of stock of Navire Pharma, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

**Page 1, Part II, Line 16**

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §1001, §1011, and §1012

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► YES

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here**  
Signature ► Stephen Bardin Date ► 1/28/2021  
Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of Bekker</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 315 shares of its common stock (“New Shares”) per 1,000 shares of stock of Orfan Biotech Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

**Page 1, Part II, Line 16**

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §1001, §1011, and §1012

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here**  
Signature ► Stephen Bardin Date ► 1/28/2021  
Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>[Signature]</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 133 shares of its common stock (“New Shares”) per 1,000 shares of stock of Origin Biosciences, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Origin Biosciences, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► YES

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ► Stephen Bardin Date ► 1/28/2021

Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP			Firm's EIN ►	13-5381590
	Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503			Phone no.	616-774-7000

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 75 shares of its common stock (“New Shares”) per 1,000 shares of stock of Phoenix Tissue Repair, Inc (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

**Page 1, Part II, Line 16**

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §1001, §1011, and §1012

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ▶ NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here**  
Signature ▶ Stephen Bardin Date ▶ 1/28/2021  
Print your name ▶ Stephen Bardin Title ▶ VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>[Signature]</i>	12/14/2020		P00439876
	Firm's name ▶ BDO USA, LLP	Firm's EIN ▶ 13-5381590		Phone no. 616-774-7000	
Firm's address ▶ 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 109 shares of its common stock (“New Shares”) per 1,000 shares of stock of QED Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from QED Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ► Stephen Bardin Date ► 1/28/2021  
 007DCCFA87FE4A3...  
 Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 75 shares of its common stock (“New Shares”) per 1,000 shares of stock of Retinagenix Therapeutics, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Retinagenix Therapeutics, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ► NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ► Stephen Bardin Date ► 1/28/2021  
007DCCFA87FF4A3...

Print your name ► Stephen Bardin Title ► VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of Bekker</i>	12/14/2020		P00439876
	Firm's name ► BDO USA, LLP	Firm's EIN ► 13-5381590		Phone no. 616-774-7000	
Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 324 shares of its common stock (“New Shares”) per 1,000 shares of stock of Theras, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Theras, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.



**Part II** Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

18 Can any resulting loss be recognized? ▶ NONE

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Sign Here**

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

DocuSigned by:  
 Signature ▶ Stephen Bardin Date ▶ 1/28/2021  
007DCCFA87FF4A3...

Print your name ▶ Stephen Bardin Title ▶ VP, Finance and Operations

<b>Paid Preparer Use Only</b>	Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
	DOUG BEKKER	<i>in of B...</i>	12/14/2020		P00439876
	Firm's name ▶ BDO USA, LLP	Firm's EIN ▶ 13-5381590		Phone no. 616-774-7000	
Firm's address ▶ 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503					

**BridgeBio Pharma, Inc.**  
**Attachment for Form 8937**  
**Report of Organizational Actions Affecting Basis of Securities**

**Page 1, Part II, Line 14**

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 211 shares of its common stock (“New Shares”) per 1,000 shares of stock of Venthera, Inc. (“Existing Shares”).

**Page 1, Part II, Line 15**

A U.S. person’s basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Venthera, Inc.

**Page 1, Part II, Line 16**

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

**Page 2, Part II, Line 17**

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

**Page 2, Part II, Line 19**

In the case of a U.S. individual taxpayer, the reportable tax year will be calendar year 2020. All taxpayers should consult with their tax advisor on the tax ramifications associated with the exchange.